Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624428 · ClinicalTrials.gov registry record · Phase 1
Varenicline on Reward Responses and Cognition in Adolescent Smokers
A Phase 1 study of Tobacco Use Disorders, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01624428 is a Phase 1 study of Tobacco Use Disorders that has completed, run by Yale University. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01624428, a Phase 1 study of Tobacco Use Disorders, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot project using functional magnetic resonance imaging (fMRI) to examine the influence of varenicline on reward processing, cognitive control, and regulation of craving in adolescent smokers. We hypothesize that adolescent smokers receiving varenicline, when compared with those receiving placebo, will have differential brain responses to anticipation of rewards, during exposure to the Stroop task, and in response to tobacco cues.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (1)
Connecticut
- Substance Abuse Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624428
The ClinicalTrials.gov registry entry for NCT01624428 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01624428 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01624428 about?
NCT01624428 is a clinical study titled "Varenicline on Reward Responses and Cognition in Adolescent Smokers". This is a pilot project using functional magnetic resonance imaging (fMRI) to examine the influence of varenicline on reward processing, cognitive control, and regulation of craving in adolescent smokers. We hypothesize that adolescent smokers receiving varenicline, when compared with those receivin...
What is the current status of trial NCT01624428?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-06. Estimated completion is 2013-12.
What conditions does trial NCT01624428 study?
This clinical trial studies the following conditions: Tobacco Use Disorders.
What interventions are being tested in trial NCT01624428?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT01624428?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01624428 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.